Research
Hormonal
GLP-1 receptor agonists reduce the risk of Major Adverse Cardiovascular Events (MACE) by 13-26% in patients with type 2 diabetes and high cardiovascular risk.
If you have type 2 diabetes and heart disease or high heart risk, GLP-1 medications like semaglutide or liraglutide are recommended not just for blood sugar, but to protect your heart. Studies show they can lower the risk of heart attacks and strokes by 13-26% compared to placebo.
StrongSupportsVERY_HIGH confidence
The LEADER study showed that liraglutide reduced the risk of Major Adverse Cardiovascular Events (MACE) by 13% in individuals with T2DM and high cardiovascular risk compared to placebo... The SUSTAIN-6 trial showed a more remarkable decrease in the risk of MACE with semaglutide... Semaglutide reduced MACE by 26%, while liraglutide decreased it by 13%.
Why this rating
Based on large outcome trials (LEADER, SUSTAIN-6) and meta-analyses.
Source
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review
Khalid M Hamed et al. · Cureus · 2024
narrative_reviewCited 39×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →